C4 Therapeutics, Inc.
CCCC
CCCC: C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
moreShow CCCC Financials
Recent trades of CCCC by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CCCC's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Compounds for targeted degradation of brd9 Jul. 04, 2023
-
Patent Title: Isoindolinone and indazole compounds for the degradation of egfr Jun. 13, 2023
-
Patent Title: Spirocyclic compounds Apr. 11, 2023
-
Patent Title: Spirocyclic compounds Feb. 21, 2023
-
Patent Title: Degraders and degrons for targeted protein degradation Dec. 13, 2022
-
Patent Title: N/o-linked degrons and degronimers for protein degradation Oct. 04, 2022
-
Patent Title: Tricyclic degraders of ikaros and aiolos Aug. 09, 2022
-
Patent Title: Dihydroquinolinones for medical treatment Aug. 02, 2022
-
Patent Title: Dihydrobenzimidazolones for medical treatment Feb. 22, 2022
-
Patent Title: Spirocyclic degronimers for target protein degradation Nov. 30, 2021
-
Patent Title: Heterocyclic degronimers for target protein degradation Feb. 02, 2021
-
Patent Title: C3-carbon linked glutarimide degronimers for target protein degradation Dec. 01, 2020
-
Patent Title: Spirocyclic degronimers for target protein degradation May. 26, 2020
-
Patent Title: Heterocyclic degronimers for target protein degradation May. 12, 2020
Federal grants, loans, and purchases
Followers on CCCC's company Twitter account
Number of mentions of CCCC in WallStreetBets Daily Discussion
Recent insights relating to CCCC
Recent picks made for CCCC stock on CNBC
ETFs with the largest estimated holdings in CCCC
Flights by private jets registered to CCCC